Skip to main content Help with accessibility Skip to main navigation

Secukinumab

Indication

For treating non-radiographic axial spondyloarthritis.

NICE TA719 - Secukinumab for treating non-radiographic axial spondyloarthritis

Red

Brand:

Nice TA:

719

Commissioning responsibility:

CCG

PbR excluded:

Yes

BNF chapter:
Musculoskeletal system

Background

1.1 Secukinumab is recommended as an option for treating active non-radiographic axial spondyloarthritis with objective signs of inflammation (shown by elevated C-reactive protein or MRI) that is not controlled well enough with non-steroidal anti-inflammatory drugs (NSAIDs) in adults. It is recommended only if:

  • tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and

  • the company provides secukinumab according to the commercial arrangement.

Recommendation

LSCMMG Recommendation:

Red

Reason for decision:

Specialist medicine

Supporting documents:

Decisions of Lancashire local decision making groups

BwD
BP
CSR
EL
FW
GP
MB
WL
Red
Red
Red
Red
Red
Red
Red
Red
What do the colours mean?

Last Updated: 10 - Sep - 2021